54.3 F
San Diego
Thursday, Mar 28, 2024
-Advertisement-

Equillium Prepares $86M IPO

La Jolla-based Equillium intends to raise $86 million through an initial public offering, according to recently filed U.S. Securities and Exchange Commission paperwork.

The company, which applied to list on the Nasdaq exchange under EQ, is developing treatments for autoimmune and inflammatory diseases.

Equillium’s lead drug, EQ001, aims to treat acute graft-versus-host disease, or aGVHD. This occurs after a transplant, when immune cells from the donor attack the host patient’s tissues.

The company is planning a phase 1b/2 clinical trial, with top-line results from the phase 1b part within a year of the trial’s start date.

As of June 30, the company had seven full-time employees, according to SEC paperwork.

-Advertisement-

Featured Articles

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-